PPT-Updates in the Treatment of Breast cancer

Mohammad Jahanzeb MD FACP Professor of Clinical Medicine HematologyOncology Director UM Sylvester Deerfield Campus Associate Center Director for Community Outreach Sylvester Comprehensive Cancer Center. Dr. Courtney A. Vito, MD, FACS. Assistant Clinical Professor of . Surgcal. Oncology. City of Hope National Medical Center . 12/8/2014. Disclosures. No relevant financial disclosures. Serve as PI for the . For Fellows November 2016. American Cancer Society, 2015 Statistics. Risk Factors. Female. Age: median 57-62. Family history. Previous biopsies. Atypical changes. BRCA positive. Hormone replacement. Alcohol use. October 25,2017. Disclosures. None. Outline. Epidemiology. Risk Factors. Screening. Diagnosis. Treatment. Genetic testing. Research. Epidemiology. 2017 :estimated 252.710 new cases of invasive breast cancer in women. Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. Survivorship. Mary Helen Hackney, M.D., FACP. VCU Massey Cancer Center. March 2013. I have no disclosures . I am employed by VCU. 2008 Estimated US Cancer Deaths*. ONS=Other nervous system.. Source: American Cancer Society, 2008.. Julie R. Gralow, M.D.. Director, Breast Medical Oncology. Jill Bennett Endowed Professor of Breast Cancer. Professor, Global Health. University of Washington School of Medicine. Fred Hutchinson Cancer Research Center. Steven J. Katz MD MPH. Professor of Medicine and Health Management and Policy. University of Michigan . Allison Kurian MD M Sc.. Professor of Medicine and Medical Genetics . Stanford University . Guidelines 2019. Cleveland Clinic Florida. Breast Surgeon . September 25, 2018. Breast Cancer . Highly prevalent disease . Limited to female sex in all but < 1% of cases in USA. SEER . Cancer. . Stat Facts: Female Breast Cancer. Lauren Barney. April 17, 2013. Breast Cancer Subtypes. Breast cancer is classified into clinical subtypes based upon receptor expression. These subtypes dictate possible therapeutic options and vary in their prognosis. Azeez Farooki, MD. Attending Physician, Clinical Member. Memorial Sloan Kettering Cancer Center. New York, NY. Objectives. Elucidate the problem of aromatase inhibitor induced bone loss and increased risk of fractures in breast cancer.  breast tissue, . most . commonly from the inner lining . of.  milk ducts or the lobules that supply the . ducts . with . milk.. Breast cancer may be invasive or noninvasive. . Invasive. Key recommendations. 1. National and local workforce planning is essential. Health Education England and all Cancer Alliances should urgently ensure there are enough healthcare professionals to deliver high-quality and timely diagnosis, treatment and care to local women.. Gavin Buckley. Supervisor: . Dr.. Malgorzata . Krajewska. School of Biochemistry and Cell Biology, University College Cork . 1. Transcriptional Cyclin-Dependent Kinases . CDK12. Promotes transcription elongation.. 1. Breast Cancer Prepared by:Hai LamLynn YuRacheal Richie Trina Jones2. 3. Pathophysiologyhttp://www.youtube.com/watch?v=YNUBnX9JHQs&feature=relatedhttp://www.youtube.com/watch?v=hswn7HlLkls&feature=related4. Clinical ManifestationsLumpMost...